Shares of the medtech companyIsoRay, Inc. (NYSEMKT:ISR) swung into massive gains once more for the second day Thursday. The shares closed at $3.30, up 29.41 percent, and having surged to new one-year high earlier in the session. That was a positive tracking of the Wednesday big gain where the shares went up as much as 80 percent on solid volume of shares changing hands. IsoRay, Inc. (NYSEMKT:ISR) shares after opening at $2.78 moved to $2.90 on last trade day and at the end of the day closed at $2.42. Company price to sales ratio in past twelve months was calculated as 20.21 and price to cash ratio as 21.13. IsoRay, Inc. (NYSEMKT:ISR) showed a positive weekly performance of 118.02%.
The Novavax, Inc. (NASDAQ:NVAX) on Mar. 10 reported its financial results for the fourth quarter and year ended December 31, 2013. Novavax reported a net loss of $14.1 million, or $0.07 per share, for the fourth quarter of 2013, compared to a net loss of $8.0 million, or $0.06 per share, for the fourth quarter of 2012. For the full year 2013, the net loss was $52.0 million, or $0.31 per share, compared to a net loss of $28.5 million, or $0.22 per share, for 2012. Novavax revenue in the fourth quarter of 2013 increased 92% to $8.7 million as compared to $4.6 million for the same period in 2012. Novavax, Inc. (NASDAQ:NVAX) shares fell -5.65% in last trading session and ended the day on $4.68. NVAX return on equity ratio is recorded as -41.40% and its return on assets is -34.10%.Novavax, Inc. (NASDAQ:NVAX) yearly performance is 117.67%.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) had its price target raised by analysts at UBS AG from $185.00 to $202.00. They now have a “buy” rating on the stock. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares moved down -7.99% in last trading session and was closed at $159.79, while trading in range of $157.76-$177.07. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) year to date performance is 20.25%.
Incyte (NASDAQ:INCY) had its price target upped by Argus from $65.00 to $85.00 in a research note issued to investors on Monday, American Banking & Market News reports. The firm currently has a buy rating on the stock.Incyte Corporation (NASDAQ:INCY) weekly performance is -3.27%. On last trading day company shares ended up $59.41. Incyte Corporation (NASDAQ:INCY) distance from 50-day simple moving average is % -7.24. Analysts mean target price for the company is $73.07.